LC
PRQR icon

Lindbrook Capital’s ProQR Therapeutics PRQR Stock Holding History

Lindbrook Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,135
Closed -$5.66K – 2905
2024
Q4 		$5.66K Buy
+2,135
New +$6.78K ﹤0.01% 1929
2022
Q1 		– Sell
-2,025
Closed -$16K – 2591
2021
Q4 		$16K Sell
2,025
-14,311
-88% -$109K ﹤0.01% 1106
2021
Q3 		$137K Buy
16,336
+3,736
+30% +$24.4K 0.04% 216
2021
Q2 		$85K Buy
12,600
+3,000
+31% +$19.3K 0.02% 326
2021
Q1 		$63K Buy
9,600
+9,000
+1,500% +$46K 0.01% 371
2020
Q4 		$3K Hold
600
– – ﹤0.01% 1366
2020
Q3 		$3K Sell
600
-682
-53% -$3.57K ﹤0.01% 1302
2020
Q2 		$8K Buy
1,282
+445
+53% +$2.4K ﹤0.01% 919
2020
Q1 		$5K Sell
837
-563
-40% -$4.32K ﹤0.01% 1010
2019
Q4 		$14K Buy
1,400
+800
+133% +$6.23K ﹤0.01% 835
2019
Q3 		$3K Buy
600
+300
+100% +$2.4K ﹤0.01% 1204
2019
Q2 		$2K Hold
300
– – ﹤0.01% 1259
2019
Q1 		$4K Sell
300
-1,300
-81% -$19.4K ﹤0.01% 1133
2018
Q4 		$25K Buy
+1,600
New +$29.4K 0.01% 537

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Lindbrook Capital's PRQR Position: Q1 2025 in Review

Lindbrook Capital sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 2,135 shares — an estimated $5.66K sold.

Lindbrook Capital first reported a position in PRQR in Q4 2018 and held it in 14 quarters. The position peaked at $137K in Q3 2021. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

  • Lindbrook Capital reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 2,135 ProQR Therapeutics shares in Q1 2025, an estimated $5.66K.
  • Lindbrook Capital first reported a position in ProQR Therapeutics in Q4 2018 and held it in 14 quarters.
  • Lindbrook Capital's ProQR Therapeutics position peaked at $137K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.